Study Of Safety, Tolerability And Effects Of PF-05175157 In Adults With Moderate To Severe Acne Vulgaris

• Status: Withdrawn
• Trial end date: 2014-10-01
• Target enrollment: 0
• Participant gender: Male

Summary

This is a 6 week study to characterize the safety, tolerability and effects of PF-05175157 administered for 6 weeks in subjects with moderate to severe acne vulgaris.

• Phase: Phase 2
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Pfizer

Criteria

Inclusion Criteria:

• Males 18 years or older diagnosed with moderate to severe acne vulgaris who are otherwise healthy.

• Normal spirometry at screening (FEV1 and FVC (Forced Vital Capacity)at least 80% predicted).

• Minimum of 20 inflammatory lesions on the face.

• Willing to discontinue other acne treatments prior to and during the study period through follow-up.

Exclusion Criteria:

• Subjects with active nodulocystic acne.

• Subjects unwilling to comply with lifestyle guidelines, commit to study visits, and perform study procedures.

• History of dry eye or other known disease that affects the sclera or cornea.

• History of pulmonary disease or inability to adequately perform testing.